Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(7):1047–1054. doi: 10.1054/bjoc.2001.2042

Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer

E Song 1,2, J Chen 2, N Ouyang 1, F Su 2, M Wang 1,2, U Heemann 1
PMCID: PMC2375090  PMID: 11592778

Abstract

Expression of membrane-bound Fas ligand (mFasL) on colon cancer cells serves as a potential mechanism to inhibit host immune function by inducing apoptosis of host lymphocytes. Membrane-bound FasL can be cleaved and released as a soluble mediator (sFasL), which may spread the apoptosis induction effect. Our study examined whether colon adenocarcinoma cells release sFasL, and induce apoptosis of host lymphocytes without direct cell–cell contact. In 12 consecutive patients with colon adenocarcinoma mFasL was identified in the tumours, sFasL was measured in the sera and apoptosis identified in tumour-infiltrating and peripheral blood lymphocytes. To analyse the function of sFasL, colon cancer cells were primarily cultured; sFasL was isolated from supernatants, measured, incubated with Fas-bearing Jurkat cells, and the resulting apoptosis was analysed. Serum levels of sFasL were significantly elevated in all colon cancer patients with mFasL expression in tumour tissues (n = 8). In these patients, the number of apoptotic lymphocytes was significantly increased within tumour and peripheral blood. Furthermore, sFasL was present in the corresponding supernatants and induced apoptosis of Jurkat cells in a dose-dependent manner. These findings suggest that mFasL-positive colon cancer cells release sFasL, and thus may induce apoptosis of host lymphocytes as a potential mechanism for immune evasion. © 2001 Cancer Research Campaignhttp://www.bjcancer.com

Keywords: soluble Fas ligand, colon neoplasms, apoptosis, immune evasion

Full Text

The Full Text of this article is available as a PDF (138.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderson M. R., Tough T. W., Davis-Smith T., Braddy S., Falk B., Schooley K. A., Goodwin R. G., Smith C. A., Ramsdell F., Lynch D. H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med. 1995 Jan 1;181(1):71–77. doi: 10.1084/jem.181.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R. C. A role for CD95 ligand in preventing graft rejection. Nature. 1995 Oct 19;377(6550):630–632. doi: 10.1038/377630a0. [DOI] [PubMed] [Google Scholar]
  3. Bennett M. W., O'Connell J., O'Sullivan G. C., Brady C., Roche D., Collins J. K., Shanahan F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol. 1998 Jun 1;160(11):5669–5675. [PubMed] [Google Scholar]
  4. Bennett M. W., O'connell J., O'sullivan G. C., Roche D., Brady C., Kelly J., Collins J. K., Shanahan F. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut. 1999 Feb;44(2):156–162. doi: 10.1136/gut.44.2.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Das H., Imoto S., Murayama T., Kajimoto K., Sugimoto T., Isobe T., Nakagawa T., Nishimura R., Koizumi T. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br J Haematol. 1999 Mar;104(4):795–800. doi: 10.1046/j.1365-2141.1999.01246.x. [DOI] [PubMed] [Google Scholar]
  6. Ghio M., Contini P., Mazzei C., Brenci S., Barberis G., Filaci G., Indiveri F., Puppo F. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood. 1999 Mar 1;93(5):1770–1777. [PubMed] [Google Scholar]
  7. Griffith T. S., Brunner T., Fletcher S. M., Green D. R., Ferguson T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995 Nov 17;270(5239):1189–1192. doi: 10.1126/science.270.5239.1189. [DOI] [PubMed] [Google Scholar]
  8. Halapi E. Oligoclonal T cells in human cancer. Med Oncol. 1998 Dec;15(4):203–211. doi: 10.1007/BF02787202. [DOI] [PubMed] [Google Scholar]
  9. Hunt J. S., Vassmer D., Ferguson T. A., Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol. 1997 May 1;158(9):4122–4128. [PubMed] [Google Scholar]
  10. Kato K., Ohshima K., Ishihara S., Anzai K., Suzumiya J., Kikuchi M. Elevated serum soluble Fas ligand in natural killer cell proliferative disorders. Br J Haematol. 1998 Dec;103(4):1164–1166. doi: 10.1046/j.1365-2141.1998.01095.x. [DOI] [PubMed] [Google Scholar]
  11. Korbutt G. S., Elliott J. F., Rajotte R. V. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes. 1997 Feb;46(2):317–322. doi: 10.2337/diab.46.2.317. [DOI] [PubMed] [Google Scholar]
  12. Krammer P. H., Dhein J., Walczak H., Behrmann I., Mariani S., Matiba B., Fath M., Daniel P. T., Knipping E., Westendorp M. O. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev. 1994 Dec;142:175–191. doi: 10.1111/j.1600-065x.1994.tb00889.x. [DOI] [PubMed] [Google Scholar]
  13. Krammer P. H., Galle P. R., Möller P., Debatin K. M. CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv Cancer Res. 1998;75:251–273. doi: 10.1016/s0065-230x(08)60744-7. [DOI] [PubMed] [Google Scholar]
  14. Liu Q. Y., Rubin M. A., Omene C., Lederman S., Stein C. A. Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res. 1998 Jul;4(7):1803–1811. [PubMed] [Google Scholar]
  15. Luo J. S., Kammerer R., Schultze H., von Kleist S. Modulations of the effector function and cytokine production of human lymphocytes by secreted factors derived from colorectal-carcinoma cells. Int J Cancer. 1997 Jul 3;72(1):142–148. doi: 10.1002/(sici)1097-0215(19970703)72:1<142::aid-ijc20>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  16. Luo J. S., Kammerer R., von Kleist S. Comparison of the effects of immunosuppressive factors from newly established colon carcinoma cell cultures on human lymphocyte proliferation and cytokine secretion. Tumour Biol. 2000 Jan-Feb;21(1):11–20. doi: 10.1159/000030106. [DOI] [PubMed] [Google Scholar]
  17. Matsumoto J., Kawai S., Terao K., Kirinoki M., Yasutomi Y., Aikawa M., Matsuda H. Malaria infection induces rapid elevation of the soluble Fas ligand level in serum and subsequent T lymphocytopenia: possible factors responsible for the differences in susceptibility of two species of Macaca monkeys to Plasmodium coatneyi infection. Infect Immun. 2000 Mar;68(3):1183–1188. doi: 10.1128/iai.68.3.1183-1188.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Matute-Bello G., Liles W. C., Steinberg K. P., Kiener P. A., Mongovin S., Chi E. Y., Jonas M., Martin T. R. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). J Immunol. 1999 Aug 15;163(4):2217–2225. [PubMed] [Google Scholar]
  19. Mukai M., Bohgaki T., Notoya A., Kohno M., Tateno M., Kobayashi S. Liver dysfunction due to apoptosis in a patient with systemic lupus erythematosus. Lupus. 2000;9(1):74–77. doi: 10.1177/096120330000900115. [DOI] [PubMed] [Google Scholar]
  20. Murayama T., Koizumi T., Das H., Kobayashi Y., Kajimoto K., Sugimoto T., Imoto S., Nishimura R., Nakagawa T. Soluble fas ligand in natural killer cell lymphoma. Am J Hematol. 1999 Dec;62(4):253–255. doi: 10.1002/(sici)1096-8652(199912)62:4<253::aid-ajh11>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  21. Nagata S., Golstein P. The Fas death factor. Science. 1995 Mar 10;267(5203):1449–1456. doi: 10.1126/science.7533326. [DOI] [PubMed] [Google Scholar]
  22. O'Connell J., Bennett M. W., O'Sullivan G. C., Roche D., Kelly J., Collins J. K., Shanahan F. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol. 1998 Nov;186(3):240–246. doi: 10.1002/(SICI)1096-9896(199811)186:3<240::AID-PATH173>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  23. O'Connell J., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996 Sep 1;184(3):1075–1082. doi: 10.1084/jem.184.3.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Oyaizu N., Kayagaki N., Yagita H., Pahwa S., Ikawa Y. Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells. Biochem Biophys Res Commun. 1997 Sep 18;238(2):670–675. doi: 10.1006/bbrc.1997.7357. [DOI] [PubMed] [Google Scholar]
  25. Sato K., Kimura F., Nakamura Y., Murakami H., Yoshida M., Tanaka M., Nagata S., Kanatani Y., Wakimoto N., Nagata N. An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br J Haematol. 1996 Aug;94(2):379–382. doi: 10.1046/j.1365-2141.1996.d01-1799.x. [DOI] [PubMed] [Google Scholar]
  26. Schneider P., Bodmer J. L., Holler N., Mattmann C., Scuderi P., Terskikh A., Peitsch M. C., Tschopp J. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol Chem. 1997 Jul 25;272(30):18827–18833. doi: 10.1074/jbc.272.30.18827. [DOI] [PubMed] [Google Scholar]
  27. Shiota G., Oyama K., Noguchi N., Takano Y., Kitaoka S., Kawasaki H. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis. Res Commun Mol Pathol Pharmacol. 1998 Jul;101(1):3–12. [PubMed] [Google Scholar]
  28. Song E., Chen J., Ouyang N., Wang M., Exton M. S., Heemann U. Kupffer cells of cirrhotic rat livers sensitize colon cancer cells to Fas-mediated apoptosis. Br J Cancer. 2001 May 4;84(9):1265–1271. doi: 10.1054/bjoc.2000.1737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sotozono C., Sano Y., Suzuki T., Tada R., Ikeda T., Nagata S., Kinoshita S. Soluble Fas ligand expression in the ocular fluids of uveitis patients. Curr Eye Res. 2000 Jan;20(1):54–57. [PubMed] [Google Scholar]
  30. Sporer B., Koedel U., Goebel F. D., Pfister H. W. Increased levels of soluble Fas receptor and Fas ligand in the cerebrospinal fluid of HIV-infected patients. AIDS Res Hum Retroviruses. 2000 Feb 10;16(3):221–226. doi: 10.1089/088922200309313. [DOI] [PubMed] [Google Scholar]
  31. Strand S., Hofmann W. J., Hug H., Müller M., Otto G., Strand D., Mariani S. M., Stremmel W., Krammer P. H., Galle P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med. 1996 Dec;2(12):1361–1366. doi: 10.1038/nm1296-1361. [DOI] [PubMed] [Google Scholar]
  32. Stuart P. M., Griffith T. S., Usui N., Pepose J., Yu X., Ferguson T. A. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997 Feb 1;99(3):396–402. doi: 10.1172/JCI119173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Takeda K., Ohara E., Kaneda T., Hashimoto K., Sasaki M. [Increased serum soluble Fas ligand in hyperthyroid Graves' disease]. Rinsho Byori. 1999 Oct;47(10):961–965. [PubMed] [Google Scholar]
  34. Tanaka M., Itai T., Adachi M., Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998 Jan;4(1):31–36. doi: 10.1038/nm0198-031. [DOI] [PubMed] [Google Scholar]
  35. Tanaka M., Suda T., Haze K., Nakamura N., Sato K., Kimura F., Motoyoshi K., Mizuki M., Tagawa S., Ohga S. Fas ligand in human serum. Nat Med. 1996 Mar;2(3):317–322. doi: 10.1038/nm0396-317. [DOI] [PubMed] [Google Scholar]
  36. Thynne G. S., Moertel C. G., Silvers A. Preoperative lymphocyte counts in peripheral blood in patients with colorectal neoplasms: a correlation with tumor type, Dukes' classification, site of primary tumor, and five-year survival rate in 1,000 patients. Dis Colon Rectum. 1979 May-Jun;22(4):221–222. doi: 10.1007/BF02586878. [DOI] [PubMed] [Google Scholar]
  37. Toyozaki T., Hiroe M., Tanaka M., Nagata S., Ohwada H., Marumo F. Levels of soluble Fas ligand in myocarditis. Am J Cardiol. 1998 Jul 15;82(2):246–248. doi: 10.1016/s0002-9149(98)00300-2. [DOI] [PubMed] [Google Scholar]
  38. Younes M., Schwartz M. R., Ertan A., Finnie D., Younes A. Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer. 2000 Feb 1;88(3):524–528. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES